| |
Geometric mean (95% CI) (model 1)
|
p-trend
|
%Δ
|
|---|
|
< 0.86
|
0.86–0.93
|
> 0.93
|
|---|
|
N
|
180
|
176
|
182
| | |
|
Median BMI (kg/m2)
|
24.0
|
26.0
|
29.0
| | |
|
Estrone
|
265.63 (196.64–358.83)
|
280.96 (208.05–379.43)
|
332.58 (247.85–446.28)
|
0.03
|
25.2
|
|
Unconjugated
|
59.62 (50.09–70.96)
|
57.50 (48.32–68.41)
|
65.72 (55.47–77.88)
|
0.18
|
10.2
|
|
Conjugated
|
195.47 (136.03–280.86)
|
215.62 (149.69–310.61)
|
261.63 (183.72–372.58)
|
0.02
|
33.8
|
|
Estradiol
|
25.85 (19.75–33.82)
|
25.68 (19.62–33.60)
|
30.30 (23.19–39.59)
|
0.16
|
17.2
|
|
Unconjugated
|
17.65 (13.75–22.66)
|
17.14 (13.38–21.96)
|
20.13 (15.63–25.92)
|
0.23
|
14
|
|
Conjugated
|
4.11 (2.15–7.84)
|
4.49 (2.34–8.61)
|
5.05 (2.64–9.67)
|
0.28
|
23
|
|
2-Hydroxyestrone
|
55.59 (48.69–63.48)
|
50.51 (44.35–57.51)
|
54.15 (47.66–61.52)
|
0.66
|
− 2.6
|
|
2-Hydroxyestradiol
|
8.99 (6.59–12.27)
|
8.83 (6.53–11.96)
|
9.19 (6.83–12.37)
|
0.78
|
2.3
|
|
2-Methoxyestrone
|
22.16 (18.06–27.20)
|
21.67 (17.70–26.54)
|
21.32 (17.62–25.80)
|
0.58
|
− 3.8
|
|
Unconjugated
|
9.79 (7.81–12.26)
|
8.36 (6.67–10.49)
|
8.25 (6.64–10.24)
|
0.03
|
− 15.7
|
|
Conjugated
|
9.40 (7.00–12.63)
|
10.65 (7.98–14.20)
|
10.96 (8.44–14.23)
|
0.20
|
16.6
|
|
2-Methoxyestradiol
|
12.73 (9.96–16.28)
|
12.52 (9.72–16.12)
|
12.84 (10.02–16.46)
|
0.89
|
0.9
|
|
Unconjugated
|
3.20 (2.57–3.98)
|
2.84 (2.28–3.53)
|
2.76 (2.22–3.43)
|
0.02
|
− 13.7
|
|
Conjugated
|
7.85 (5.57–11.06)
|
8.42 (5.92–11.99)
|
8.98 (6.37–12.65)
|
0.18
|
14.3
|
|
2-Hydroxyestrone-3-methyl ether
|
3.66 (2.94–4.57)
|
3.64 (2.94–4.52)
|
3.76 (3.05–4.64)
|
0.72
|
2.6
|
|
4-Hydroxyestrone
|
7.04 (5.14–9.66)
|
7.27 (5.25–10.06)
|
7.35 (5.37–10.05)
|
0.61
|
4.3
|
|
4-Methoxyestrone
|
3.93 (3.15–4.90)
|
3.41 (2.75–4.22)
|
3.58 (2.90–4.43)
|
0.14
|
− 8.8
|
|
4-Methoxyestradiol
|
1.46 (1.18–1.80)
|
1.51 (1.22–1.87)
|
1.57 (1.28–1.93)
|
0.26
|
7.6
|
|
16α-Hydroxyestrone
|
31.89 (22.93–44.34)
|
32.62 (23.35–45.57)
|
42.96 (31.11–59.32)
|
0.003
|
34.7
|
|
Estriol
|
82.26 (66.81–101.28)
|
91.05 (74.10–111.88)
|
102.32 (83.39–125.56)
|
0.01
|
24.4
|
|
Unconjugated
|
9.21 (8.28–10.25)
|
10.13 (9.01–11.39)
|
9.40 (8.47–10.43)
|
0.62
|
2
|
|
Conjugated
|
71.43 (56.65–90.07)
|
77.59 (61.76–97.49)
|
90.38 (72.03–113.40)
|
0.01
|
26.5
|
|
16-Ketoestradiol
|
17.82 (14.10–22.51)
|
18.56 (14.71–23.41)
|
22.85 (18.09–28.86)
|
0.002
|
28.2
|
|
16-Epiestriol
|
17.45 (13.81–22.04)
|
17.79 (14.15–22.36)
|
19.87 (15.80–24.98)
|
0.08
|
13.9
|
|
17-Epiestriol
|
25.37 (19.23–33.49)
|
27.06 (20.42–35.87)
|
26.27 (19.89–34.70)
|
0.63
|
3.5
|
- Geometric means adjusted for age at blood draw (continuous), blood draw year (2013, 2014, 2015), smoking status (never, former, current, missing), diabetes (yes, no, missing), time since menopause (≤ 2, 3–5, 6–10, > 10, missing), ever used oral contraceptives (yes, no, missing)
- p-trend was estimated using the Wald test for ordinal WHR category
- %Δ indicates the percentage change in estrogen/estrogen metabolite levels, comparing women with highest WHR tertile to lowest WHR tertile, and was estimated by taking the ratio of the geometric mean difference in estrogen/estrogen metabolite levels between women with highest WHR tertile minus lowest WHR tertile to the geometric mean of women with lowest WHR tertile, multiplied by 100
- Bold p-values represent FDR ≤ 0.05
